The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Urology|
|State||Published - 1988|
ASJC Scopus subject areas